MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: Risk Capital_Angel, Venture (VC), Strategic Corporate( CVC), Private Equity (PE), Mergers and Acquisition (M&A) (Trends)
*Driving Forces: Risk Capital_Angel, Venture (VC), Strategic Corporate( CVC), Private Equity (PE), Mergers and Acquisition (M&A) (Facts & Figures)
Venture-Geographic Data
*Bioscience Regional Clusters & HotSpots
*Industry: Maryland (Medical & Health Information Technology, Biomedical, Biopharmaceutical & Biotechnology Sectors)
Glyscend Therapeutics
Organization & Developments: Glyscend Therapeutics
Parents
Glyscend Therapeutics
Children
* Orally administered, non-absorbed, gut-restricted duodenal exclusion therapy replicates metabolic effects of bariatric surgery
*Oral, gut-targeted polymer therapeutics for treatment of metabolic indications such as type 2 diabetes, and other chronic conditions.
Company has novel oral polymer therapy for patients with T2D and other metabolic diseases.
Jumps
Finance & Acquisition: Glyscend Therapeutics
Key People: Glyscend Therapeutics